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Abstract The axonal microtubule-associated protein, tau, is 
thought to play an important role in axonal growth and in the 
establishment of neuronal polarity. In adult human brain there are 
six alternatively spliced tau isoforms, which have different micro- 
tubule binding afflnlties in vitro. The tubulin-tau interaction is 
further mod&d by phosphorylation of tau and, compared to 
adult brain tau, both foetal brain tau and paired helical tilament 
(PHF) tau, characteristic of Alzhehner’s disease, are hyper- 
phosphorylated. In vivo both the expression of tau isoforms and 
their phosphorylation states are developmentally regulated. In 
order to establish the correlation between the expression of tau 
isoforms and their pattern of phosphorylation, we have character- 
ised these two features in several in vitro models of neuronal 
differentiation, including the human neuroblastoma cell lines, SK- 
N-SH, SH-SYSY and IMR32 cells, rat PC12 cells and primary 
rat cortical neurones. Sensitive RT-PCR analysis revealed a dif- 
ferent complement of tau isoforms in the different cell lines and 
neuritogenesis was associated mainly with an increase in the 
overall tau protein level with no apparent phosphorylation 
changes. A switch in tau isoform expression occurred only at the 
terminal stages of neuronal development, when it may be impor- 
tant in reinforcing the previously established axonal cytoarchitec- 
ture. 
r&v words: Tau; Neuronal differentiation; Cytoskeleton; 
!‘hosphorylation; Alzheimer’s disease 
1. Introduction 
The neuronal microtubule-associated protein, tau, appears 
IO play a major role in the polymerisation and stabilisation of 
rnicrotubules during axonal elongation. Indeed, inhibition of 
:au expression in cultured cerebellar neurones results in a loss 
bf axon formation [1,2] whereas over-expression of tau in non- 
!leuronal insect cells leads to production of neurite-like proc- 
tsses [3]. Because of the different requirement for microtubule 
ilynamics and stability during axonal elongation [4,5], the bind- 
I ng of tau to microtubules has to be modulated during develop- 
ment; this is achieved at both the transcriptional and post- 
1 ranslational levels. 
Tau is encoded by a single gene but, in the adult human 
i)rain, is expressed as six alternatively spliced isoforms. The 
~soforms differ in having either three or four imperfect homol- 
l)gous repeat sequences in the C-terminal half of the molecule 
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and each of these two variants have either none, one or two 
inserts towards the N-terminus [6,7]. Isoforms with four C- 
terminal repeats have a higher affinity for microtubules than 
isoforms with three such repeats; the N-terminal inserts do not 
appear to contribute to microtubule binding [8]. Tau is a 
phosphoprotein and dephosphorylated tau has a higher micro- 
tubule assembly promoting activity than native tau [9]. In addi- 
tion, tau phosphorylated in vitro by certain kinases has a re- 
duced affinity for microtubules [lo-121. 
Only the smallest isoform, i.e. with no N-terminal inserts and 
three C-terminal repeats, is expressed in the foetal brain and 
during early postnatal development (approximately postnatal 
day 10 in the rat) [6,13]. There is a switch in RNA splicing to 
produce adult tau isoforms that is concomitant with a marked 
reduction in tau phosphorylation. Decrease in the level of tau 
phosphorylation during development essentially occurs by loss 
of phosphorylation at (Ser/Thr)-Pro sites [ 13- 161 leaving only 
a proportion of tau in a similar phosphorylation state in the 
adult brain [17,18]. 
Tau is the principal component of the paired helical filaments 
(PHF), characteristic of the neurodegenerative pathology of 
Alzheimer’s disease [19-211. Tau associated with PHF (PHF- 
tau), is phosphorylated at the same (Ser/Thr)-Pro sites as foetal 
brain tau [13-161. Despite this similarity in phosphorylation 
state, PHF are not formed in foetal brain. This is possibly 
because only the single shortest isoform is expressed in foetal 
brain or because PHF-tau is phosphorylated at additional sites 
compared to foetal tau [22]. Nevertheless, this has led to the 
proposal that a pathological neurotrophic response in Alz- 
heimer’s disease may re-activate the kinaseslphosphatases re- 
sponsible for tau phosphorylation in the juvenile brain, thus 
contributing to PHF formation via the inappropriate hyper- 
phosphorylation of the full complement of adult brain tau 
isoforms. 
The expression of different tau isoforms and the regulation 
of their phosphorylation in developing rat brain has been well 
documented [6,7,13-161. However, since neurones from differ- 
ent areas of the brain do not extend their axons in a coordinated 
manner, a precise correlation between isoform expression and 
pattern of phosphorylation of tau has not been established. In 
the present study we characterised the expression and phospho- 
rylation of tau during neurite outgrowth in several cultured 
neuronal cells. Our results suggest that, whereas early neurite 
outgrowth is associated with an overall increase in tau protein 
expression, the change in the splicing pattern of tau isoforms 
is a later event. Moreover, there were no detectable changes in 
the pattern of tau phosphorylation with respect to differentia- 
tion. 
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2. Materials and Methods 
2.1. Cell culture 
SHSY5Y, their parent cell line, SK-N-SH [23] and lMR32 human 
neuroblastoma cells were routinely grown in DMEM supplemented 
with 10% (v/v) foetal bovine serum (FBS). In order to induce differen- 
tiation, SH-SYSY cells were plated at 4 x 10’ cells/cm* and incubated 
with IO PM retinoic acid (RA) in DMEM supplemented with 1% (v/v) 
FBS. Cells were maintained in retinoic acid for up to three weeks at 
which stage a stable neuronal population had been established and 
retinoic acid was omitted from the medium. IMR32 cells were induced 
to differentiate by a single addition of 10 PM bromodeoxyuridine 
(BrDU). PC12 cells were routinely grown on collagen in RPM11640 
supplemented with 10% (v/v) FBS and 5% (v/v) horse serum (HS). For 
differentiation, cells were replated at 2 x lo4 cells/cm’ and grown in 
RPM1 supplemented with 1% (v/v) HS and 0.5% (v/v) FBS in the 
presence of 50 ng/ml /I-NGF. Fresh differentiation medium was added 
every 334 days and control cells were cultured similarly in the absence 
of NGF. Primary dissociated rat brain cortical neuronal cultures were 
routinely established from embryonic day 17-18 (E17-E18) foetuses 
and maintained in DMEMlF12 (4: 1) supplemented with 2% (v/v) FBS 
and essential supplements [24]. Postnatal cultures were established from 
3-day-old (P3) pups by using a similar protocol. 
2.2 Anulysis of tau isoform expression 
Total RNA was extracted from cells by the guanidium isothiocya- 
nate/acid phenol method [25] and 2 pg of each sample was reverse 
transcribed using an oligo(dT) primer and AMV reverse transcriptase 
(Promega, Southampton, England). The synthesised cDNAs were then 
subjected to 30 cycles of amplification by PCR using two pairs of 
primers to detect specifically either the N-terminal inserts or the C- 
terminal repeats in the tau cDNA, as previously described [13]. Ol- 
igonucleotide primer pairs were chosen according to the published rat 
[6] and human [7] tau cDNA sequences. PCR products were analyzed 
on 2% (w/v) Nu-sieve agarose gels and visualised with ethidium bro- 
mide. 
2.3 Tau protein extraction and Western blot analysis 
Cells were harvested in PBS and an aliquot was retained for subse- 
quent protein determination by the Bradford method (Bio-Rad, Hemel 
Hempstead, England). Laemmli sample buffer was added to a second 
aliquot of the cells which was then boiled. The remaining cells were used 
to prepare a tau-enriched heat-stable fraction, as previously described 
[13]. Briefly, cells were lysed in Mes/NaCl buffer (100 mM Mes, 0.5 mM 
MgCl,, 1 M NaCl, 2 mM DTT, 1 mM PMSF, 50 mM NaF, 0.1 mM 
NaVO,, pH 6.5) and immediately boiled for 5 min before cooling on 
ice. Following centrifugation at 20,000 x g,, for 20 min, the superna- 
tant, containing tau, was diluted with Laemmh sample buffer and 
boiled. Equivalent loadings of total cell protein fractions or heat-stable 
preparations were run on 10% (w/v) SDS-PAGE gels and electro- 
phoretically transferred to nitrocellulose. Nitrocellulose membranes 
were then blocked in 10% (w/v) semi-fat dried milk, 0.2% (w/v) Tween- 
20 in TBS and probed with various tau antibodies. Immunoreactivity 
was revealed using an alkaline phosphatase conjugated secondary anti- 
body and BCIP/NBT substrate (Bio-rad). For dephosphorylation, pre- 
blocked nitrocellulose membranes were incubated for 16 hat 37°C with 
1 U/ml of E. coli alkaline phosphatase (type III-N, Sigma, Poole, Eng- 
land) in 50 mM TrislHCl, pH 8.3, containing 50 mM NaCI, 1 mM 
MgC&, I mM .&Cl, and 1 mM PMSF [26]. Control membranes were 
treated identically except for the addition of 0.2 M Na/K-phosphate, 
pH 8.3, to inhibit the phosphatase activity. Dephosphorylation of heat- 
soluble tau preparations prior to gel migration was carried out under 
similar conditions after spin dialysis against the alkaline phosphatase 
buffer using a Centricon- microconcentrator (Amicon, Stonehouse, 
England). 
2.4 Antibodies 
Antibodies 8073 [27] and TP70 [24] are rabbit polyclonal antisera 
raised against normal human brain tau or a carboxy-terminal I4 amino 
acid human tau peptide, respectively. The monoclonal antibody Tau 1 
recognises a potentially phosphorylated epitope at Ser-199/Ser-202 of 
tau when it is not phosphorylated. 8D8, SM131 and SM1310 are all 
neurofilament monoclonal antibodies that recognise phosphorylated 
epitopes in both neurofilaments and tau [28,29]. 
C.J. Smith et (11. IFEBS Letters 375 (1995) 243-248 
3. Results 
In order to determine which tau isoforms were expressed in 
the different cultured cells examined and to investigate changes 
in their pattern of expression in relation to neuronal differen- 
tiation, mRNA was qualitatively analyzed by a sensitive reverse 
transcription-PCR (RT-PCR) technique. For this purpose, re- 
verse transcribed mRNA was amplified by using pairs of prim- 
ers flanking the N-terminal insert or the C-terminal repeat 
domains of tau. Typical results are shown in Fig. 1. Undifferen- 
tiated human neuroblastoma cells, SH-SYSY (lanes 1) and their 
parent cell line, SK-N-SH (lanes 2) expressed principally the 
shortest tau isoform (i.e. tau isoforms with no N-terminal in- 
serts and three C-terminal repeats). Forms with four C-terminal 
repeats are also expressed, but, given the limitation of PCR as 
a quantitative technique, at a much lower level than three re- 
peat isoforms. After 3 to 4 weeks in culture in the presence of 
retinoic acid, these cells establish a non-proliferative neuronal 
population with extensive neurites, expressing the adult neu- 
rofilament triplet proteins [30]. No significant changes in the 
pattern of tau expression following differentiation of SH-SYSY 
cells for up to 25 days were observed. Undifferentiated IMR 
32 cells also mainly express the shortest tau isoform, however, 
in cells terminally differentiated following a 28 day treatment 
with BrDU, tau isoforms with N-terminal inserts, particularly 
two inserts, began to appear (Fig. lA, lanes 3). Even consider- 
ing the difficulty in quantifying PCR data, there was also 
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Fig. 1. RT-PCR analysis of tau isoform expression in cultured neuronal 
cells. (A) Reverse transcribed DNA amplified with a pair a primers 
detecting the N-terminal insert domains of tau. Arrowheads on the 
left-hand side indicate the positions of human tau isoforms with no, one 
or two N-terminal inserts. Arrowheads on the right-hand side indicate 
the positions of similar isoforms of rat tau, that are slightly smaller than 
the corresponding human isoforms. (B) Reverse transcribed DNA am- 
plified with a pair a primers detecting the C-terminal repeats of tau. 
Arrowheads to the left of the figure indicate the positions of tau 
isoforms with three or four C-terminal inserts. Lanes 1: SH-SYSY cells 
exposed to RA for 0,9, 17 and 25 days; lanes 2: SK-N-SH cells, control 
and 28 days with RA; lanes 3: IMR32 cells, control and 28 days with 
BrDU; lanes 4: PC12 cells, 0, 10 and 17 days with NGF; lanes 5: 
postnatally (P3) established primary rat cortical cultures after 10 days 
in vitro; rat brain extracts from P3 and PlO animals. 
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I ig. 2. Western blots showing tau protein expression and phosphorylation in cultured neuronal cells. (A) SH-SY5Y cells; lanes 1: PHF-tau; lanes 
Z undifferentiated cells; lanes 3 and 4: cells differentiated for 14 and 21 days, respectively. (B) IMR 32 cells differentiated for 28 days with BrDU. 
(11) PC12 cells; lanes 1: undifferentiated cells; lanes 2, 3 and 4: cells differentiated for 7, 1 I and 17 days, respectively. (D) P3 rat primary neurones 
after 10 (lanes 1) and 18 (lanes 2) days in vitro. Western blots were stained with the following antibodies: 8073 (a), TP70 (b), Tau 1 (c). 8D8 (d), 
SMI310 (e) and SMI31 (I). The bands at about 140 kDa detected with 8D8, SM1310 and SM131 are neurofilament subunits. In addition. 8D8 labels 
1 vo unidentified slower-migrating species in undifferentiated SH-SYSY cells (A, d, lane 2). Bars to the left of the panels indicate the positions of 
1 ie molecular weight markers: phosphorylase b, 97.4 kDa; catalase, 58.1 kDa and alcohol dehydrogenase. 39.8 kDa. 
( Pig. lB, lanes 3). Undifferentiated rat pheochromocytoma 
1 ‘Cl2 cells expressed a mixture of longer tau isoforms (i.e. one 
; nd two N-terminal inserts with both three and four C-terminal 
I :peats) but little of the shortest isoform (Fig. 1, lanes 4). 
1 nfferentiation of PC12 cells using low density cultures and low 
szrum resulted in the formation of an extensive neuritic net- 
vrork which could be maintained for at least one month in 
culture. However, as in SH-SYSY and SK-N-SH cells, there 
was no change in tau isoform expression in relation to differen- 
I ation. 
Rat cortical neurones in primary cultures established from 
P3 animals and maintained for 10 days in vitro contained 
isoforms with three and four C-terminal repeats; forms with 
one or two N-terminal inserts just began to appear (Fig. 1A and 
B, lanes 5). This pattern is similar to that of PlO rat brain, 
whereas tau in P3 rat brain is still principally composed of the 
shortest isoform. However, an adult pattern of tau isoforms 
was not observed in cultures established from El 8 foetal brain 
tissue and maintained for up to one month in vitro (data not 
shown). 
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Fig. 3. Tau is partially hyperphosphorylated in SH-SYSY cells. Heat-stable tau preparations from undifferentiated SH-SYSY cells were 
dephosphorylated with alkaline phosphatase either prior to SDS-PAGE (A) or on nitrocellulose subsequent to Western blotting (B). Lanes 1: control; 
lanes 2: dephosphorylated preparation. The blots were stained with 8073 (a) or Tau 1 (b). Note the increased migration rate of dephosphorylated 
tau in (A) as well as increased Tau 1 inununoreactivity following dephosphorylation. Molecular weight markers are as in Fig. 2. 
When examined by Western blotting, tau from the various 
cell lines appears as multiple bands. The number of bands 
detected in tau is determined by its isoform composition and 
its state of phosphorylation, that affects electrophoretic mobil- 
ity [9]. This is illustrated in Fig. 2 for SH-SY5Y, IMR32 and 
PC12 cells as well as for P3 rat brain primary cortical neurones. 
The principal tau species in SH-SYSY cells (Fig. 2A), as well 
as in IMR 32 cells (Fig. 2B) or in rat cortical neurones (Fig. 
2D), migrated as a broad band or doublet at around 50 kDa. 
Consistent with the RT-PCR analyses, PC12 tau migrated as 
several bands in the 55-65 kDa range, together with high mo- 
lecular weight tau at around 110 kDa (Fig. 2C). 
In SH-SYSY and PC12 cells differentiated for up to 3 weeks, 
as well as in primary cortical neurones, a major feature of 
neuronal differentiation was an overall increase in the level of 
tau protein with little change in the band pattern of tau species. 
This is best illustrated by the labelling with the polyclonal 
antibodies, 8073 and TP70, which recognise all brain tau 
isoforms largely independently of their phosphorylation state 
(Fig. 2A, C and D, a and b). For each cell type, the same total 
amount of protein was loaded in each lane so that increased 
immunoreactivity represents an increase in the proportion of 
tau in the samples. 
Western blots were also probed with a panel of antibodies 
binding to tau in a phosphorylation-dependent manner (Fig. 
2A-D, c-f). These included the monoclonal antibody, Tau 1 
(Fig. 2A-D, c), recognizing Ser-199/Ser-202 of the longest 
human tau isoform when unphosphorylated and the neurofil- 
ament monoclonal antibodies, 8D8, SM1310 and SM131, that 
recognise phosphorylated neurofilaments as well as tau 
phosphorylated at specific sites (Fig. 2A-D, d-f). For instance 
8D8 recognises Ser-396 of human tau in a phosphorylated state 
and the epitope for SM131 and SM1310 is centred around 
Ser-396 and Ser-404. These sites are in regions conserved be- 
tween rat and human tau. The fraction of tau labelled by the 
neurofilament antibodies was always the slowest-migrating 
component of the total cellular tau. Tau in all the cultured cells 
stained with either Tau 1 or the neurofilament antibodies, indi- 
cating that a proportion of tau was phosphorylated. However, 
the pattern of immunoreactive species was different for each 
cell type. For example, in SH-SYSY cells, the slow migrating 
tau species stained by 8D8 (Fig. 2A, d) had a weak reactivity 
for 8073 which strongly labelled faster migrating tau (Fig. 2A, 
a), indicating that most of the tau in SH-SYSY cells was not 
phosphorylated at Ser-396. On the other hand, most of the tau 
in rat cortical neurones appears phosphorylated at Ser-396 
(Fig. 2D, a and d). 
Although an absolute quantification was not performed, 
there was no overt change in the proportion of hyper- 
phosphorylated tau occurring during differentiation of the cell 
type examined (Fig. 2A, C and D, d and f). The 110 kDa high 
molecular weight tau present in PC12 cells was also partially 
phosphorylated (Fig. 2C, c and d). The monoclonal antibodies 
8D8, SM1310 and SM131 also detected neurofilament polypep- 
tides at about 140 kDa, this is particularly clear for IMR 32 
cells (Fig. 2B, d and e) and for rat cortical neurones (Fig. 2D, 
d and f). 
Faster-migrating and slower-migrating tau species were also 
detectable in the neuroblastoma cells and primary neurones, 
albeit in minor quantities, suggesting the presence of 
dephosphorylated and longer tau isoforms, respectively. In 
order to investigate further the basis for this heterogeneity, tau 
extracted from undifferentiated SH-SYSY cells, which ex- 
pressed almost exclusively the shortest tau isoform, was 
dephosphorylated in vitro and analyzed by Western blotting. 
Treatment of tau from SH-SYSY cells with alkaline phosphat- 
ase resulted in a dramatic electrophoretic shift and in an altered 
immunoreactivity, as illustrated in Fig. 3A. Following 
dephosphorylation, the principal tau species migrated at about 
42 kDa, as opposed to 50 kDa in untreated samples, and la- 
belled intensely with the Tau 1 antibody. Partial phosphoryla- 
tion of tau at the Tau 1 epitope in SH-SYSY cells was con- 
firmed by the increase in Tau 1 immunoreactivity after treat- 
ment of nitrocellulose-bound tau with alkaline phosphatase 
(Fig. 3B). 
4. Discussion 
In the developing brain there is a switch in tau expression 
from the single shortest isoform to multiple adult isoforms, 
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which occurs at about postnatal day 10 in the rat [6,13]. This 
switch is coincident with reduced tau phosphorylation and has 
been related to a reduction in neuronal plasticity and reinforce- 
ment of mature neuronal cytoarchitecture. 
Our results in several different in vitro models of neuronal 
cjifferentiation, indicate that an overall increase in tau protein 
1 :vels is coincident with neurite outgrowth. This could either be 
t ue to an increase in tau expression of to a reduced sensitivity 
#f tau to proteolysis after its transport into neurites. Another 
‘nicrotubule-associated protein, MAP2, has been shown to be 
nore stable in dendrites than in axons and neuronal cell bodies 
311. A switch in tau isoform expression would be a much later 
vent; it is even possible that, in some neuronal systems, includ- 
ng primary cultures established from foetal brain, that the 
xpression of mature isoforms may never occur [32]. 
The presence of multiple tau isoforms in PC12 cells contrasts 
vith the single shortest isoform present in other cell lines. How- 
‘ver, the presence of mature tau isoforms in undifferentiated 
‘Cl2 cells does not inhibit neurite extension. It thus appears 
hat the absolute level rather than the complement of tau 
soforms is the key factor in early neurite outgrowth. This is 
:onsistent with tau transfection experiments, where over-ex- 
lression of tau induces processes in the non neuronal insect Sl9 
:ells [3] and accentuates neurite outgrowth in PC12 cells [33]. 
,ikewise, the inhibition of tau expression in cerebellar neurones 
nhibits differentiation of exploratory neurites into axons [I]. 
It thus appears that altered tau isoform expression is not 
necessary for extensive neuritic development although equally, 
he presence of multiple tau isoforms does not impede early 
teuronal differentiation in PC12 cells. 
Our observations on tau phosphorylation in the human neu- 
.oblastoma cell line, SH-SYSY confirmed those reported by 
Tanaka et al. [34], who also found phosphorylation of tau at 
Ser-199/Ser-202, Ser-396 and Ser-404 in undifferentiated SH- 
SYSY cells and during their early differentiation. In addition 
we showed that, after long term differentiation, when a mature 
reuronal phenotype is obtained, there is no overt change in the 
oattern of tau phosphorylation. However, the immunofluores- 
:ence reactivity of SH-SYSY tau for PHF-1, a monoclonal 
urtibody to tau phosphorylated at Ser-396, increases during 
differentiation to a neuronal phenotype and redistributes from 
the soma to elaborating neurites [35]. This, together with our 
results indicates that phosphorylated tau may undergo confor- 
mational changes or changes in its interaction with other pro- 
teins during differentiation that would, in turn, result in the 
unmasking of the PHF-1 epitope. We found no evidence for a 
significant change in the phosphorylation pattern of tau in 
association with neuronal differentiation. Thus, a minor frac- 
tion of the total cellular tau was phosphorylated at Ser-199/Ser- 
202 and/or at Ser-396/Ser-404 in all of the cell lines investigated, 
independently of their differentiation state. As the developmen- 
tal change in tau phosphorylation in vivo coincides with the 
expression of mature tau isoforms [ 131, it is perhaps not surpris- 
ing that no phosphorylation changes in vitro were observed. 
However, alterations in tau phosphorylation at these serine 
residues may not be an important regulatory control for micro- 
tubule properties during neuronal differentiation. Regulation 
of tau phosphorylation at other residues, particularly Ser-262 
which influences microtubule binding in vitro, may be more 
significant [ 11,121. It is also possible that differentially 
phosphorylated forms of tau are associated with different sub- 
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populations of microtubules or localized in different subcellular 
compartments. It is interesting that tau phosphorylation is not 
obviously affected by the arrest in cell division associated with 
the initiation of neuronal differentiation in neuroblastoma and 
PC 12 lines. Proline-directed kinases, including cell cycle-de- 
pendent kinases, phosphorylate tau in vitro [10,26,36,37] and 
there is a recent report of increased immunoreactivity for the 
antibody PHF-1 (recognizing phosphorylated Ser-396) in mi- 
totic SH-SYSY cells [38] therefore classical cell cycle-dependent 
kinases may have a role in tau phosphorylation. 
With regard to unravelling the processes that underlie tau 
hyperphosphorylation in Alzheimer’s disease, it is noteworthy 
that all of these neuronal culture models possess a fraction of 
PHF-like tau which is phosphorylated at Ser-202 and/or Ser- 
396/Ser-404. Furthermore, in the presence of phosphatase in- 
hibitors, the majority of tau accumulates in a hyper- 
phosphorylated state [39,40]. Therefore it appears that all of 
these cell lines possess some of the kinases necessary to generate 
PHF-tau epitopes. The effect of okadaic acid on tau phospho- 
rylation. as has been reported previously, is only apparent when 
ceils are irreversibly poisoned. 
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